Current Rating and Its Significance
MarketsMOJO’s 'Strong Sell' rating for Dishman Carbogen Amcis Ltd indicates a cautious stance for investors, suggesting that the stock is expected to underperform relative to the broader market and its sector peers. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the company’s investment potential and risk profile.
Quality Assessment
As of 26 February 2026, the company’s quality grade remains below average. This is reflected in its weak long-term fundamental strength, with an average Return on Capital Employed (ROCE) of just 0.97%. Such a low ROCE indicates that the company is generating minimal returns on the capital invested, which is a concern for long-term value creation. Furthermore, net sales have grown at a modest annual rate of 8.10% over the past five years, signalling limited top-line expansion in a competitive pharmaceuticals and biotechnology sector.
Valuation Perspective
Despite the challenges in quality, the valuation grade is currently very attractive. This suggests that the stock is priced at a level that could offer value relative to its earnings and asset base. However, attractive valuation alone does not offset the risks posed by weak fundamentals and deteriorating financial trends. Investors should consider whether the low price adequately compensates for the underlying business risks.
Financial Trend Analysis
The financial trend for Dishman Carbogen Amcis Ltd is negative. The latest quarterly figures show a net profit after tax (PAT) loss of ₹12.97 crores, representing a steep decline of 403.0%. Operating profit before interest, depreciation, and taxes (PBDIT) is also at a low ₹113.11 crores. The company’s ability to service debt is strained, with a high Debt to EBITDA ratio of 4.96 times and an operating profit to interest coverage ratio of only 2.47 times. These metrics highlight significant financial stress and raise concerns about the company’s capacity to sustain operations without further financial restructuring or capital infusion.
Technical Outlook
Technically, the stock is bearish. Recent price movements show a 5.86% gain in the last trading day, but this is overshadowed by declines over longer periods: -1.66% over one week, -11.60% over one month, and -23.50% over three months. Year-to-date, the stock has fallen by 24.57%, and over the past year, it has delivered a negative return of 12.41%. This underperformance relative to the BSE500 index over multiple time frames reflects weak investor sentiment and limited buying interest.
Investor Participation and Market Sentiment
Institutional investors, who typically have greater resources and expertise to analyse company fundamentals, have reduced their stake by 0.51% in the previous quarter, now collectively holding 8.93% of the company. This decline in institutional participation may signal concerns about the company’s prospects and adds to the bearish technical outlook.
Implications for Investors
For investors, the 'Strong Sell' rating serves as a cautionary signal. It suggests that the stock currently carries elevated risks due to weak financial health, poor profitability, and negative market sentiment. While the valuation appears attractive, the underlying quality and financial trends indicate that the company faces significant challenges that could impact future returns. Investors should carefully weigh these factors and consider their risk tolerance before taking a position in this stock.
Summary of Key Metrics as of 26 February 2026
- Mojo Score: 17.0 (Strong Sell grade)
- Market Capitalisation: Smallcap segment
- Return on Capital Employed (ROCE): 0.97%
- Net Sales Growth (5-year CAGR): 8.10%
- Debt to EBITDA Ratio: 4.96 times
- Operating Profit to Interest Coverage: 2.47 times
- Quarterly PAT: -₹12.97 crores (down 403.0%)
- Stock Returns: 1D +5.86%, 1W -1.66%, 1M -11.60%, 3M -23.50%, 6M -31.65%, YTD -24.57%, 1Y -12.41%
- Institutional Holding: 8.93% (down 0.51% last quarter)
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Sector and Market Context
Dishman Carbogen Amcis Ltd operates within the Pharmaceuticals & Biotechnology sector, a space characterised by rapid innovation and intense competition. While the sector overall has shown resilience and growth potential, this company’s current financial and operational challenges place it at a disadvantage compared to peers. Investors looking to capitalise on sector growth may prefer companies with stronger fundamentals and more robust financial trends.
Conclusion
In conclusion, the 'Strong Sell' rating assigned to Dishman Carbogen Amcis Ltd by MarketsMOJO reflects a comprehensive evaluation of its current financial health, valuation, quality, and technical outlook. As of 26 February 2026, the company faces significant headwinds, including weak profitability, high leverage, and declining investor confidence. While the stock’s valuation may appear enticing, the risks inherent in its financial and operational profile suggest that investors should approach with caution. This rating serves as a guide for investors to prioritise capital preservation and consider alternative opportunities within the sector or broader market.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
